Immunovant (IMVT) Income from Continuing Operations (2018 - 2026)
Immunovant's (IMVT) quarterly Income from Continuing Operations came in at 147841000.0 in Q1 2026, down 38.88% YoY from 241903663.08 in Q1 2025, and down 33.63% on a QoQ basis from 110635000.0 in Q4 2025.
Immunovant (IMVT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Income from Continuing Operations data on file, last reported at 147841000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 38.88% year-over-year to 147841000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 505591000.0 (down 22.17% YoY) and the FY2026 annual result came in at 505591000.0, down 22.17% from the prior year.
- Income from Continuing Operations eased to 147841000.0 in Q1 2026, from 110635000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 40373000.0 in Q2 2022 to a low of 147841000.0 in Q1 2026.
- A 5-year average of 84523411.76 and a median of 75319000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations climbed 18.68% — and 2024, when it plunged 116.11%.
- Tracing IMVT's Income from Continuing Operations over 5 years: stood at 63227000.0 in 2022, then advanced by 18.68% to 51418000.0 in 2023, then sank by 116.11% to 111122000.0 in 2024, then advanced by 0.44% to 110635000.0 in 2025, then plunged by 33.63% to 147841000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 147841000.0 (Q1 2026), 110635000.0 (Q4 2025), and 126502000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | -153.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -153.22 Mn |
| Mar 31, 2026 | -147.84 Mn |
| Dec 31, 2025 | -110.64 Mn |
| Sep 30, 2025 | -126.50 Mn |
| Jun 30, 2025 | -120.61 Mn |
| Mar 31, 2025 | -106.45 Mn |
| Dec 31, 2024 | -111.12 Mn |
| Sep 30, 2024 | -109.12 Mn |
| Jun 30, 2024 | -87.15 Mn |
| Mar 31, 2024 | -75.32 Mn |
| Dec 31, 2023 | -51.42 Mn |
| Sep 30, 2023 | -58.66 Mn |
| Jun 30, 2023 | -73.94 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -63.23 Mn |
| Sep 30, 2022 | -47.93 Mn |
| Jun 30, 2022 | -40.37 Mn |
| Mar 31, 2022 | -47.17 Mn |
| Dec 31, 2021 | -41.39 Mn |
| Sep 30, 2021 | -37.70 Mn |